December 2013

Contents

Editorial

• Volume 14 Number 11/12 November/December 2013

Supplements

• Guide to HIV and HCV coinfection (November 2013)

Conference reports

• 44th Union World Conference on Lung Health, 30 October – 3 November 2013, Paris

• Preventing and treating TB in children – more baby steps

• 14th European AIDS Conference (EACS), 16-19 October 2013, Brussels

• Dolutegravir superior to darunavir/r at week 48 in open label treatment naïve study

• GSK744: 24-week results with oral integrase inhibitor planned for once-monthly injections

• Cenicriviroc: 48 week results compared to efavirenz

• Approaches to once-daily raltegravir: new formulation likely to require food

• DSMB stops boosted atazanavir monotherapy study due to virological failure

• Recreational drug use is common in HIV positive gay men and is extensive in a significant minority

• Caution against prolonged use of bisphosphonates in patients with mild-moderate fracture risk

• Osteoporosis triples risk of later fracture in 1000-person US HIV group

• Bone turnover marker changes early in ART predict bone loss after 96 week

• Low HDL cholesterol is main lipid abnormality in HIV+/HIV- comparison

• Classic risk factors, but not HIV, linked to arterial stiffness in middle-aged

Antiretrovirals

• Elvitegravir approved in EU: data on food and drug interactions

• ViiV file 572-trii fixed dose combination in the US: positive opinion to approve dolutegravir in the EU

Treatment access

• Obama increases US contribution to Global Fund to $5 billion over three years

• HIV struggle in South Africa undermined by medicine stockouts and mismanagement

Paediatric care

• Paediatric guidelines on the prevention and treatment of OIs (November 2013)

Guidelines

• European guidelines launched at EACS (2013)

• US HIV guidelines update information on integrase inhibitors (Oct 2013)

Side effects

• Efavirenz is associated with higher suicide risk in meta-analysis of four ACTG studies

Hepatitis coinfection

• EU recommends approval of sofosbuvir for HCV

• Compassionate use of declatasvir with sofosbuvir for people in urgent need of HCV treatment

HIV prevention and transmission

• The little blue pill that can stop HIV: PROUD study enrolling gay men in the UK

Basic science and immunology

• Dual HIV infection in long term nonprogressor elite controllers

On the web

• Online journals

PDFs

• Volume 14 Number 11/12 November/December 2013 PDF